Treatment of minimal Daudi lymphoma disease with LL2-onconase or component proteins.

Daudi lymphoma cells (5 × 10⁶ cells) were injected ip, followed 1 day later for an additional 4 consecutive days with ip injections of PBS (open triangles), 80 μg LL2 (open circles), 20 μg onconase (open squares), 80 μg LL2 + 20 μg onconase (open diamonds), or 100 μg LL2-onconase (solid squares) as described in “Materials and methods.” The mice treated with LL2-onconase survived significantly longer than PBS (P < .001); LL2 (P < .02); onconase (P < .001); LL2 plus onconase (P < .02).